ESR1 and cancer: Entinostat, a class I HDAC (HDAC1 and HDAC3) inhibitor, upregulates the expression of ERα in ER-negative and ER-positive breast cancers and enhances the sensitivity of cancer cells to endocrine therapy, especially in ER-silent metastatic breast cancer [208,209,210].